主页 > 医学前沿 >
【medical-news】起搏器数据支持他汀类药物的抗心
8 August 2008
MedWire News: Statin treatment may help to prevent atrial fibrillation (AF) recurrence, suggests an observational study of patients implanted with a pacemaker.
"Randomized clinical trials are warranted to test the hypothesis that statins prevent AF in patient populations at risk for AF," say Anne Gillis (University of Calgary, Alberta, Canada) and colleagues.
As reported in the European Heart Journal, the team analyzed memory data from pacemakers implanted in 185 patients who had experienced at least three episodes of AF during a previous year. In all, 85% of patients experienced recurrence during the year after pacemaker implantation.
Patients who suffered AF recurrence were significantly more likely to be on statin therapy than those who did not, at 54% versus 25% (p=0.0004).
The probably of patients experiencing AF recurrence was 0.63 in those taking statins, compared with 0.85 in those not taking statins, which corresponds to a 22% reduction in the absolute risk for recurrence.
Patients taking statins were more likely to be male, taking a beta blocker or Class I/III anti-arrhythmic drug, and to have coronary artery disease. After accounting for these variables plus age, hypertension, and left ventricular ejection fraction, statin use remained significantly associated with a 67% relative reduction in the risk for AF (p=0.007).
In an accompanying editorial, Carsten Israel (JW Goethe University Hospital, Frankfurt, Germany) said: "The results are particularly valuable because a continuously active AF monitor in the form of a pacemaker with a highly reliable AF detection algorithm was used."
He explained that conventional diagnostic monitoring fails to detect about 70% of AF recurrences.
Israel stressed, however, that statins failed to prevent 63% of AF recurrences in the current study cohort, which had established paroxysmal or persistent AF. The study therefore "raises the question of whether the use of statins at an earlier stage (eg, before documentation of the first AF episode) may be valuable in preventing AF, which would best be addressed, again, using implantable devices as monitors," he concluded.
Eur Heart J 2008; 29: 1798-1799, 1873-1880
http://www.incirculation.net/NewsItem/Pacemaker-data-support-statin-antiarrhythmic-prope.aspx 已阅，谢谢lz提供好文。 Pacemaker data support statin anti-arrhythmic properties
起搏器数据支持他汀类药物的抗心律失常作用
8 August 2008
2008年8月8日
MedWire News: Statin treatment may help to prevent atrial fibrillation (AF) recurrence, suggests an observational study of patients implanted with a pacemaker.
医学在线新闻：他汀类药物治疗可能有助于预防心房颤动（AF）复发，一项对植入起搏器患者的观察性研究显示。
"Randomized clinical trials are warranted to test the hypothesis that statins prevent AF in patient populations at risk for AF," say Anne Gillis (University of Calgary, Alberta, Canada) and colleagues.
“需要有随机临床研究来验证他汀类药物能用于AF高危患者预防AF的假说，”Anne Gillis（卡尔加里大学，阿尔伯塔省，加拿大）及其同事说。
As reported in the European Heart Journal, the team analyzed memory data from pacemakers implanted in 185 patients who had experienced at least three episodes of AF during a previous year. In all, 85% of patients experienced recurrence during the year after pacemaker implantation.
欧洲心脏杂志报道，该研究团队分析了185例植入起搏器患者的起搏器记忆数据，这些患者既往曾有过至少3次房颤发作。共有85%的患者在植入起搏器后1年有过房颤复发。
Patients who suffered AF recurrence were significantly more likely to be on statin therapy than those who did not, at 54% versus 25% (p=0.0004).
有房颤复发的患者接受他汀类药物显著多于没有复发的患者，54% versus 25%（P=0.0004）。
The probably of patients experiencing AF recurrence was 0.63 in those taking statins, compared with 0.85 in those not taking statins, which corresponds to a 22% reduction in the absolute risk for recurrence.
接受他汀类药物治疗的患者房颤复发率为0.63，而没有接受他汀治疗的患者复发率 为0.85，复发的绝对危险降低了22%。
Patients taking statins were more likely to be male, taking a beta blocker or Class I/III anti-arrhythmic drug, and to have coronary artery disease. After accounting for these variables plus age, hypertension, and left ventricular ejection fraction, statin use remained significantly associated with a 67% relative reduction in the risk for AF (p=0.007).
接受他汀治疗的患者有较多的男性，接受B阻滞剂，接受I/III类抗心律失常药物治疗和罹患冠心病。在校正了这些因素和年龄、高血压、左心室射血分数之后，他汀治疗仍然与房颤复发危险减少67%显著相关（P=0.007）。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-22 19:03
医学,生命科学网